Familial Adenomatous Polyposis 3 C4225157
Familial adenomatous polyposis 3 is a genetic condition leading to many colon polyps and elevated cancer risk if untreated. It is inherited in an autosomal dominant manner. Management includes routine monitoring and proactive surgical options.
Key facts at a glance
- ICD-10
- D13.91
- ICD-11
- 3A00.0
- Body system
- gastrointestinal
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Intussusception
Abdominal pain or nausea
(gastrointestinal)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Blood in stool
(gastrointestinal)Diarrhea
(gastrointestinal)Fatigue
(gastrointestinal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
GI disease management
Active treatment with regular monitoring by a healthcare provider is recommended.
Proctocolectomy with ileal pouch-anal anastomosis
Complete removal of colon and rectum with construction of an internal pouch from small intestine. Recommended for patients with severe polyposis involving the rectum or high cancer risk.
COX-2 inhibitor therapy (celecoxib)
Selective cyclooxygenase-2 inhibitors can reduce adenomatous polyp burden with potentially fewer gastrointestinal side effects than traditional NSAIDs. Part of chemoprevention strategy.
Additional treatment options
Comprehensive genetic and phenotypic surveillance
Regular monitoring including APC gene variant assessment, thyroid ultrasound, fundus examination, and desmoid tumor screening. FAP variants require vigilance for extraintestinal manifestations.
monitoringTotal abdominal colectomy with ileorectal anastomosis
Removal of entire colon with connection of small intestine to upper rectum. Suitable alternative when rectal polyp burden is minimal, preserving continence and avoiding permanent stoma.
surgicalSmoking cessation and alcohol moderation
Complete smoking cessation and limiting alcohol intake reduces overall cancer risk and supports treatment efficacy. Smoking particularly accelerates polyp progression in FAP.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Familial Adenomatous Polyposis 3 C4225157?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Familial Adenomatous Polyposis 3 C4225157. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy